AKT1 and neoplasm: A recent randomized Phase II study showed AKT inhibition with ipatasertib in combination with abiraterone showed improved anti‐tumor activity measured by radiographic progression‐free survival in mCRPCa patients, especially those with loss of PTEN signaling.